Prognostic biomarkers in patients with localized natural killer/T‐cell lymphoma treated with concurrent chemoradiotherapy
| العنوان: | Prognostic biomarkers in patients with localized natural killer/T‐cell lymphoma treated with concurrent chemoradiotherapy |
|---|---|
| المؤلفون: | Shigeo Nakamura, Masahiko Oguchi, Tomohiro Kinoshita, Nobuko Kubota, Noriko Usui, Naoki Ishizuka, Tadashi Yoshino, Kunihiro Tsukasaki, Kuniaki Itoh, Yukio Kobayashi, Kana Miyazaki, Kenichi Ishizawa, Yasushi Isobe, Yoshihiro Matsuno, Kazuo Oshimi, Kensei Tobinai, Katsuyoshi Takata, Motoko Yamaguchi, Izumi Wasada |
| المصدر: | Cancer Science |
| بيانات النشر: | Wiley, 2014. |
| سنة النشر: | 2014 |
| مصطلحات موضوعية: | Adult, Antigens, Differentiation, T-Lymphocyte, Male, Cancer Research, Pathology, medicine.medical_specialty, extranodal NK/T-cell lymphoma, medicine.medical_treatment, medicine.disease_cause, Gastroenterology, Immunophenotyping, Viral Matrix Proteins, Epstein–Barr virus, Recurrence, Internal medicine, medicine, Humans, In Situ Hybridization, radiotherapy, Aged, Neoplasm Staging, Membrane Glycoproteins, latent membrane protein 1, business.industry, Hazard ratio, Chemoradiotherapy, Original Articles, General Medicine, Middle Aged, Prognosis, medicine.disease, Natural killer T cell, Immunohistochemistry, Confidence interval, Lymphoma, Concurrent chemoradiotherapy, Lymphoma, Extranodal NK-T-Cell, Clinical trial, Radiation therapy, Treatment Outcome, Oncology, Disease Progression, Female, business, Biomarkers |
| الوصف: | Concurrent chemoradiotherapy has become one of the standard management approaches for newly diagnosed localized nasal natural killer (NK)/T-cell lymphoma (NKTCL). Few data are available on the prognostic biomarkers of NKTCL among patients treated with concurrent chemoradiotherapy. To evaluate the prognostic significance of immunophenotypic biomarkers for patients treated with concurrent chemoradiotherapy, latent membrane protein 1 (LMP1), cutaneous lymphocyte antigen (CLA) and cell origin were examined in samples from 32 patients who were enrolled in the Japan Clinical Oncology Group 0211 trial and treated with concurrent chemoradiotherapy. LMP1 and CLA were positive in 66% (19/29) and 29% (9/31) of the cases examined, respectively. The median follow-up duration was 68 months (range, 61–94). The patients with LMP1-positive tumors showed a better overall survival (OS) than the patients with LMP1-negative tumors (hazard ratio, 0.240; 95% confidence interval [CI], 0.057–1.013; 80% CI, 0.093–0.615; P = 0.035). All five patients with LMP1-negative tumors who experienced disease progression died of lymphoma, and both patients with local failure had LMP1-negative tumors. There was no significant difference in OS according to CLA expression. A total of 27 (84%) cases were of NK-cell origin, two were of αβ T-cell origin and three were of γδ T-cell origin. In contrast to those with tumors of NK-cell origin, all five patients with NKTCL of T-cell origin were alive without relapse at the last follow up. Our results indicate that LMP1 expression is a favorable prognostic marker and suggest that a T-cell origin of the tumor may be a favorable prognostic marker for patients with localized NKTCL treated with concurrent chemoradiotherapy. |
| تدمد: | 1349-7006 1347-9032 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::afc1cd30160a4e005d677075b4b75df2Test https://doi.org/10.1111/cas.12526Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....afc1cd30160a4e005d677075b4b75df2 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 13497006 13479032 |
|---|